{"product_id":"global-rapid-tests-market-size-study-forecast-by-product-instruments-consumables-others-by-technology-molecular-diagnostics-immunoassay-and-others-by-application-upper-respiratory-tract-infections-antibiotic-sepsis-by-end-use-hospitals","title":"Global Rapid Tests  Market Size study \u0026 Forecast, by Product (Instruments, Consumables, Others), by Technology ( Molecular Diagnostics, Immunoassay and Others) by Application (Upper Respiratory Tract Infections, Antibiotic, Sepsis), by End Use (Hospitals","description":"\u003cp\u003eGlobal Rapid Tests  Market Size study \u0026amp; Forecast, by Product (Instruments, Consumables, Others), by Technology ( Molecular Diagnostics, Immunoassay and Others) by Application (Upper Respiratory Tract Infections, Antibiotic, Sepsis), by End Use (Hospitals \u0026amp; Clinics,  Laboratories and At - Home Testing and Others) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Rapid Tests  Market is valued approximately USD 1.19 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.60% over the forecast period 2022-2029 Rapid tests, commonly referred to as RDTs or rapid diagnostic tests, are simple to use procedures that offer prompt answers, typically in few minutes or less. Rapid tests are performed and give results at the point of treatment, unlike the majority of regular tests, which must be forwarded to a lab. The Rapid Tests market is expanding because of factors such as increasing adoption of Self - Testing \u0026amp; Point - Of - Care Products, and introduction Of CLIA Waived Test and growing Geriatric Population Base. However,  the presence of ambiguous regulatory may halt market growth.\u003c\/p\u003e\n\n\u003cp\u003eDiabetes is one of the world's fastest-growing chronic diseases. Its prevalence has progressively increased during the last few decades. The primary factors propelling market expansion are the rising elderly population, increasing target disease burden, and increased usage of self-testing \u0026amp; point-of-care products. According to the World Health Organization, diabetes will afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric, and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Additionally, the market is expanding as a result of the introduction of technologically advanced items. However, the main difficulty with quick diagnostics solutions is quality assurance, which is expected to limit market expansion.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Rapid Tests  Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the emergence of technologically advanced products, high rates of infections with upper respiratory diseases and antibiotic resistance, and high healthcare costs Additionally, the usage of PoC \u0026amp; fast diagnostics for the diagnosis of numerous ailments in the region, as well as encouraging government initiatives, are supporting the market's expansion. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nAbbott\u003cbr\u003e\nBD (Becton, Dickinson and Company)\u003cbr\u003e\nbioMérieux SA\u003cbr\u003e\nDiaSorin S.p.A.\u003cbr\u003e\nDanaher Corporation\u003cbr\u003e\nThermo Fisher Scientific, Inc.\u003cbr\u003e\nF. Hoffmann - La Roche Ltd\u003cbr\u003e\nMeridian Bioscience, Inc.\u003cbr\u003e\nBio-rad Laboratories, Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In August 2022, Accelerate Diagnostics and BD collaborated commercially. Through this strategic strategy, BD would provide Accelerate Diagnostics' quick diagnostics for antibiotic resistance and susceptibility over the world.\u003cbr\u003e\n? In December 2022, Roche stated that the U.S. Food and Drug Administration had authorised the COVID-19 At-home Test for Emergency Use. The test involves a straightforward anterior nasal swab sample that may be easily obtained and self-tested by those age 14 and older. For children aged 2 to 13, an adult must administer the test.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Rapid Tests  Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Product, Technology, Application, , End Use, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Product:\u003cbr\u003e\nInstruments\u003cbr\u003e\nConsumables\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Technology:\u003cbr\u003e\nMolecular Diagnostics\u003cbr\u003e\nImmunoassay\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Application:\u003cbr\u003e\nUpper Respiratory Tract Infections\u003cbr\u003e\nAntibiotic\u003cbr\u003e\nSepsis\u003cbr\u003e\nBy End Use:\u003cbr\u003e\nHospitals \u0026amp; Clinics\u003cbr\u003e\nLaboratories\u003cbr\u003e\nAt - Home Testing\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nAbbott\u003cbr\u003e\nBD (Becton, Dickinson and Company)\u003cbr\u003e\nbioMérieux SA\u003cbr\u003e\nDiaSorin S.p.A.\u003cbr\u003e\nDanaher Corporation\u003cbr\u003e\nThermo Fisher Scientific, Inc.\u003cbr\u003e\nF. Hoffmann - La Roche Ltd\u003cbr\u003e\nMeridian Bioscience, Inc.\u003cbr\u003e\nBio-rad Laboratories, Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 200 Pages \/ MCW16236327","offer_id":47651473064242,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-rapid-tests-market-size-study-forecast-by-product-instruments-consumables-others-by-technology-molecular-diagnostics-immunoassay-and-others-by-application-upper-respiratory-tract-infections-antibiotic-sepsis-by-end-use-hospitals","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}